𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?

✍ Scribed by James E. Herndon II; Stewart Fleishman; Alice B. Kornblith; Michael Kosty; Mark R. Green; Jimmie Holland


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
112 KB
Volume
85
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Background:

Several studies have recently reported on the importance of quality of life (qol) in predicting the survival of patients with lung carcinoma. to confirm these reports, the relationship between survival and qol, as measured by the european organization for research and treatment of cancer (eortc) quality of life questionnaire and duke-unc social support scale, was examined within a group of 206 patients with advanced nonsmall cell lung carcinoma treated in a randomized clinical trial conducted by the cancer and leukemia group b (calgb 8931).

Methods:

Patients completed the eortc instrument and the duke-unc social support scale at baseline in the clinic. the cox proportional hazards model was used to determine the incremental contribution qol provided in predicting survival beyond the effect of known clinical prognostic variables.

Results:

Clinical factors that were jointly predictive of poorer survival included low performance status, nonadenocarcinoma histology, presence of dyspnea, weight loss greater than 5%, albumin level less than 3.5 mg/dl, and adrenal metastases. univariate analyses showed that patient-reported eortc subscales describing increased pain, appetite loss, fatigue, lung carcinoma symptoms, poorer overall qol, and poorer physical functioning predicted significantly poorer survival. multivariate analyses showed that, after adjustment for clinical factors, overall qol was not a significant predictor of survival. rather, the only eortc subscale of prognostic importance was the pain subscale, in which a 40-point increase was associated with a 27% increase in the hazard rate.

Conclusions:

This study did not confirm the prognostic importance of overall qol. rather, after adjustment for significant clinical factors, a patient-provided pain report had the greatest prognostic importance.


πŸ“œ SIMILAR VOLUMES


The impact of age on toxicity, response
✍ Thomas A. Hensing; Amy H. Peterman; Michael J. Schell; Ji-Hyun Lee; Mark A. Soci πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 109 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The optimal treatment strategy for elderly patients with advanced nonsmall cell lung carcinoma has not been defined to date. The authors performed a retrospective analysis of a Phase III trial that treated patients who had Stage IIIB or IV nonsmall cell lung carcinoma wit

Expression of bcl-2 protein is associate
✍ Chris I. Huang; Donna Neuberg; Bruce E. Johnson; Jeanne Y. Wei; David C. Christi πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 326 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The aim of this study was to assess the relationship between the expression of the 27‐kilodalton (kD) __bcl__‐2 protein and survival among nonsmall cell lung carcinoma (NSCLC) patients. ## METHODS Paired tissue samples of histologically confirmed tumor and uninvolved lu

Phase I trial of docetaxel and vinorelbi
✍ Vincent A. Miller; Kenneth K. Ng; Lee M. Krug; Wendy Perez; Barbara Pizzo; Rober πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 76 KB πŸ‘ 2 views

## Background: With preclinical evidence of synergy, this dose-finding trial examining the combination of docetaxel and vinorelbine given with prophylactic filgrastim for the treatment of patients with nonsmall cell lung carcinoma was undertaken. ## Methods: Twenty-seven patients with advanced no

First-line treatment of advanced nonsmal
✍ Charalambos Kourousis; Nicos Androulakis; Stelios Kakolyris; John Souglakos; Geo πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 2 views

BACKGROUND. Docetaxel and vinorelbine are active agents in the treatment of nonsmall cell lung carcinoma (NSCLC). The efficacy and toxicity of this combination was evaluated in a Phase II study in patients with advanced NSCLC. ## METHODS. Forty-six chemotherapy-naive patients (44 men and 2 women

Single agent versus combination chemothe
✍ Rogerio C. Lilenbaum; Patricia Langenberg; Kay Dickersin πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 2 views

## Background: This meta-analysis was conducted to compare the effects of single agent versus combination chemotherapy on response rate, toxicity, and survival of patients with advanced nonsmall cell lung carcinoma (nsclc). ## Methods: The authors reviewed randomized clinical trials published in